Recommendations for the Standardization and Interpretation of the Electrocardiogram

Part II: Electrocardiography Diagnostic Statement List

A Scientific Statement From the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society

Endorsed by the International Society for Computerized Electrocardiology

Jay W. Mason, MD, FAHA, FACC, FHRS; E. William Hancock, MD, FACC; Leonard S. Gettes, MD, FAHA, FACC

Abtract—This statement provides a concise list of diagnostic terms for ECG interpretation that can be shared by students, teachers, and readers of electrocardiography. This effort was motivated by the existence of multiple automated diagnostic code sets containing imprecise and overlapping terms. An intended outcome of this statement list is greater uniformity of ECG diagnosis and a resultant improvement in patient care. The lexicon includes primary diagnostic statements, secondary diagnostic statements, modifiers, and statements for the comparison of ECGs. This diagnostic lexicon should be reviewed and updated periodically. (J Am Coll Cardiol 2007;49:1128–35)

Key Words: AHA Scientific Statements ■ electrocardiography ■ computers ■ diagnosis

This is the second of 6 articles designed to upgrade the guidelines for the standardization and interpretation of the ECG. The project was initiated by the American Heart Association and has been endorsed by the American College of Cardiology, the Heart Rhythm Society, and the International Society for Computerized Electrocardiography. The rationale for this upgrade and a description of the process are contained in Part I by Kligfield et al (1).

The listing contained in the present statement seeks to present a limited set of ECG diagnostic statements that are clinically useful and that do not create unnecessary overlap or contain vague terminology. Some statements that are commonly used by electrocardiographers but that do not provide diagnostically or clinically useful information are not included. Some statements have been excluded to reduce the size of the statement set, so long as their meaning is well represented by included terms.

The Writing Group believes that the listing should be implemented as an available lexicon in report algorithms of the existing commercial electrocardiographs and that it should be used widely by ECG readers. The principal advantage of such use would be a worldwide improvement in uniformity of ECG interpretation. Such uniformity would promote better patient

Other members of the Standardization and Interpretation of the Electrocardiogram Writing Group include James J. Bailey, MD; Rory Childers, MD; Barbara J. Deal, MD, FACC; Mark Josephson, MD, FACC, FHRS; Paul Kligfield, MD, FAHA, FACC; Jan A. Kors, PhD; Peter Macfarlane, DSc; Olle Pahlm, MD, PhD; David M. Mirvis, MD, FAHA; Peter Okin, MD, FACC; Pentti Rautaharju, MD, PhD; Borys Surawicz, MD, FAHA, FACC; Gerard van Herpen, MD, PhD; Galen S. Wagner, MD; and Hein Wellens, MD, FAHA, FACC.

The American Heart Association, the American College of Cardiology Foundation, and the Heart Rhythm Society make every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest.

This statement was approved by the American Heart Association Science Advisory and Coordinating Committee on October 26, 2006, by the American College of Cardiology Board of Trustees on October 12, 2006, and by the Heart Rhythm Society on September 6, 2006.

When citing this document, the American Heart Association, the American College of Cardiology Foundation, and the Heart Rhythm Society request that the following citation format be used: Mason JW, Hancock EW, Gettes LS. Recommendations for the standardization and interpretation of the electrocardiogram: part II: electrocardiography diagnostic statement list: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. J Am Coll Cardiol 2007;49:1128–35.

This article has been copublished in the March 13, 2007, issue of Circulation and in the March 2007 issue of Heart Rhythm.

Copies: For copies of this document, please contact Elsevier Inc. Reprint Department, fax (212) 633-3820, e-mail reprints@elsevier.com.

Permissions: Modification, alteration, enhancement, and/or distribution of this document are not permitted without the express permission of the American Heart Association. Instructions for obtaining permission are located at http://www.americanheart.org/presenter.jhtml? Identifier=4431. A link to the "Permission Request Form" appears on the right side of the page.

care. Additional advantages would be facilitation of the establishment of a uniform teaching curriculum in electrocardiography, availability of a uniform glossary of terms for research application, and promotion of research to better validate diagnostic criteria for the specific terms in the limited lexicon.

Although we recognize that each vendor of ECGs possesses a proprietary set of diagnostic statements and underlying criteria, we hope that this list of statements will be made available by each of them so that the reader can select it as the primary dictionary for use in interpreting all or some ECGs. We are also hopeful that the vendors will collaborate among themselves to align diagnostic criteria for this specific lexicon. This would not interfere with continued development of entirely independent, proprietary diagnostic software by each manufacturer.

Organization and Use

Four lists are included within this document. The main listing (Table 1), "Primary Statements," displays 117 primary diagnostic statements under 14 categories. The majority of the primary statements are nondescriptive and convey clinical meaning without additional statements. The second listing (Table 2), "Secondary Statements," provides additional statements that can be used to expand the specificity and clinical relevance of both descriptive and other primary diagnostic statements. These secondary statements are divided into 2 groups. Those that are preceded by "suggests" invoke clinical diagnoses likely responsible for the ECG observation(s). Those that are preceded by "consider" are intended to propose at least 1, but sometimes >1, potentially associated clinical disorder. This set of primary and secondary diagnostic statements constitutes what we might call the "core statement lexicon."

The third list (Table 3) contains adjectives that can be used to modify the diagnostic statements. None of the modifiers change the meaning of the core statement but rather serve to refine the meaning. The list contains general modifiers, which can be used with many of the core statements, and specific modifiers assigned to a specific category of statements.

The fourth list (Table 4) is a short directory of comparison statements. It specifies 6 types of ECG changes that merit mention in the ECG interpretation and defines criteria to identify change within the 6 categories. Because so many statements could be made in comparing individual ECGs to

≥1 previous ECGs, the Writing Group recommends use of these 6 statements to convey clinically important information that could influence patient care by the attending physician while preserving brevity and uniformity. On the other hand, the Writing Group encourages readers to add uncoded text as needed to the report to more fully compare tracings.

Tables 5, 6, and 7 establish rules for use of the primary, secondary, and modifier statements, alone or in combination. Table 8 is a set of commonly used statements that can, for the most part, be precisely reproduced by use of the primary and secondary statements and their modifiers. These statements are commonly used concatenations provided for the convenience of the reader.

Criteria for Diagnoses

This listing does not specify diagnostic criteria for any of the statements. A single set of diagnostic criteria underlying the core statements would have great benefits for patient care and research. Although the Writing Group does not believe that a uniform criterion set can be achieved at this time, we encourage ECG vendors and electrocardiography researchers and experts to collaborate on the development of a universally acceptable criteria set and a means for perpetually refining it. Several of the chapters in this statement support specific criteria for some of the core statements.

Myocardial Infarction Terminology

Advanced imaging techniques, including echocardiography (2) and magnetic resonance (3,4), have demonstrated a need for change in existing terminology describing the cardiac location of myocardial infarction. New diagnostic statements for 6 common, distinct cardiac locations of myocardial infarction, documented by contrast-enhanced magnetic resonance, were recently recommended by a committee of the International Society for Holter and Noninvasive Electrocardiography (5). At the present time, the Writing Group considers the quantity of new data insufficient to recommend abandonment of existing terminology. Thus, traditional terms are listed in "Section M: Myocardial infarction" of the primary statement table (Table 1); however, we intend to revisit this issue when sufficient data have been developed.

Disclosures

Writing Group Disclosures

Writing Group Member	Employment	Research Grant	Other Research Support	Speakers' Bureau/Honoraria	Ownership Interest	Consultant/ Advisory Board	Other
Jay W. Mason	Covance Cardiac Safety Services	None	None	None	None	None	None
Leonard S. Gettes	University of North Carolina	None	None	None	None	None	None
E. William Hancock	Stanford University Medical Center	None	None	None	None	Philips Medical Systems,* Covance Diagnostics*	None

This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be "significant" if (1) the person receives \$10 000 or more during any 12-month period, or 5% or more of the person's gross income; or (2) the person owns 5% or more of the voting stock or share of the entity, or owns \$10 000 or more of the fair market value of the entity. A relationship is considered to be "modest" if it is less than "significant" under the preceding definition.

^{*}Significant.

1130

Reviewer Disclosures

Reviewer	Employment	Research Grant	Other Research Support	Speakers' Bureau/Honoraria	Ownership Interest	Consultant/ Advisory Board	Other
Jonathan Abrams	University of New Mexico	None	None	None	None	None	None
Leonard S. Dreifus	Hahnemann University, School of Medicine	None	None	None	None	None	Merck Endpoint Committee
Mark Eisenberg	McGill University	None	None	None	None	None	None
Nora Goldschlager	University of California, San Francisco	None	None	St. Jude; Medtronic	None	None	None
Peter Kowey	Lankenau Hospital and Main Line Health	None	None	Medifacts	Cardionet	Medifacts	None
Frank Marcus	University of Arizona	None	None	None	None	None	None
Thomas M. Munger	Mayo Clinic	St. Jude Medical, Bard Electrophysiology	None	None	None	None	None
Robert J. Myerburg	University of Miami	None	None	None	None	None	None
David Rosenbaum	Case Western Reserve University	None	None	None	None	None	None
Richard Schofield	University of Florida	None	None	None	None	None	None
Samuel Shubrooks	Beth Israel Deaconess Medical Center	None	None	None	None	None	None
Cynthia Tracy	George Washington University	None	None	None	None	None	None

This table represents the relationships of reviewers that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all reviewers are required to complete and submit.

References

- Kligfield P, Gettes L, Bailey JJ, et al. Recommendations for the standardization and interpretation of the electrocardiogram: part I: the electrocardiogram and its technology: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. J Am Coll Cardiol 2007;49:1109–27.
- Bogaty P, Boyer L, Rousseau L, Arsenault M. Is anteroseptal myocardial infarction an appropriate term? Am J Med 2002;113:37–41.
- Selvanayagam JB, Kardos A, Nicolson D, et al. Anteroseptal or apical myocardial infarction: a controversy addressed using delayed enhancement

- cardiovascular magnetic resonance imaging. J Cardiovasc Magn Reson 2004; 6:653–61.
- Bayes de Luna A, Cino JM, Pujadas S, et al. Concordance of electrocardiographic patterns and healed myocardial infarction location detected by cardiovascular magnetic resonance. Am J Cardiol 2006;97:443–51.
- 5. Bayes de Luna A, Wagner G, Birnbaum Y, et al; International Society for Holter and Noninvasive Electrocardiography. A new terminology for left ventricular walls and location of myocardial infarcts that present Q wave based on the standard of cardiac magnetic resonance imaging: a statement for healthcare professionals from a committee appointed by the International Society for Holter and Noninvasive Electrocardiography. Circulation 2006;114:1755–60.

TABLE 1. Primary Statements

A. Overall interpretation		G. Ventricular tachyarrhythmias	
1	Normal ECG	70	Ventricular tachycardia
2	Otherwise normal ECG	71	Ventricular tachycardia, unsustained
3	Abnormal ECG	72	Ventricular tachycardia, polymorphous
4	Uninterpretable ECG	73	Ventricular tachycardia, torsades de
B. Technical conditions			pointes
10	Extremity electrode reversal	74	Ventricular fibrillation
11	Misplaced precordial electrode(s)	75	Fascicular tachycardia
12	Missing lead(s)	76	Wide-QRS tachycardia
13	Right-sided precordial electrode(s)	H. Atrioventricular conduction	
14	Artifact	80	Short PR interval
15	Poor-quality data	81	AV conduction ratio N:D
16	Posterior electrode(s)	82	Prolonged PR interval
C. Sinus node rhythms and arrhythmias		83	Second-degree AV block, Mobitz type I
20	Sinus rhythm		(Wenckebach)
21	Sinus tachycardia	84	Second-degree AV block, Mobitz type I
22	Sinus bradycardia	85	2:1 AV block
23	Sinus arrhythmia	86	AV block, varying conduction
24	Sinoatrial block, type I	87	AV block, advanced (high-grade)
25	Sinoatrial block, type II	88	AV block, complete (third-degree)
26	Sinus pause or arrest	89	AV dissociation
27	Uncertain supraventricular rhythm	I. Intraventricular and intra-atrial	
). Supraventricular arrhythmias		conduction	
30	Atrial premature complex(es)	100	Aberrant conduction of supraventricular
31	Atrial premature complexes,		beat(s)
	nonconducted	101	Left anterior fascicular block
32	Retrograde atrial activation	102	Left posterior fascicular block
33	Wandering atrial pacemaker	104	Left bundle-branch block
34	Ectopic atrial rhythm	105	Incomplete right bundle-branch block
35	Ectopic atrial rhythm, multifocal	106	Right bundle-branch block
36	Junctional premature complex(es)	107	Intraventricular conduction delay
37	Junctional escape complex(es)	108	Ventricular preexcitation
38	Junctional rhythm	109	Right atrial conduction abnormality
39	Accelerated junctional rhythm	110	Left atrial conduction abnormality
40	Supraventricular rhythm	111	Epsilon wave
41	Supraventricular complex(es)	J. Axis and voltage	5
42	Bradycardia, nonsinus	120	Right-axis deviation
E. Supraventricular tachyarrhythmias		121	Left-axis deviation
50	Atrial fibrillation	122	Right superior axis
51	Atrial flutter	123	Indeterminate axis
52	Ectopic atrial tachycardia, unifocal	124	Electrical alternans
53	Ectopic atrial tachycardia, multifocal	125	Low voltage
54	Junctional tachycardia	128	Abnormal precordial R-wave progression
55	Supraventricular tachycardia	131	Abnormal P-wave axis
56	Narrow-QRS tachycardia	K. Chamber hypertrophy or	
F. Ventricular arrhythmias		enlargement	
60	Ventricular premature complex(es)	140	Left atrial enlargement
61	Fusion complex(es)	141	Right atrial enlargement
62	Ventricular escape complex(es)	142	Left ventricular hypertrophy
63	Idioventricular rhythm	143	Right ventricular hypertrophy
64	Accelerated idioventricular rhythm	144	Biventricular hypertrophy
	Fascicular rhythm		
65 66	Parasystole		

TABLE 1. Primary Statements, Cont'd

L. ST segment, T wave, and U wave		
145	ST deviation	
146	ST deviation with T-wave change	
147	T-wave abnormality	
148	Prolonged QT interval	
149	Short QT interval	
150	Prominent U waves	
151	Inverted U waves	
152	TU fusion	
153	ST-T change due to ventricular hypertrophy	
154	Osborn wave	
155	Early repolarization	
M. Myocardial infarction		
160	Anterior MI	
161	Inferior MI	
162	Posterior MI	
163	Lateral MI	
165	Anteroseptal MI	
166	Extensive anterior MI	
173	MI in presence of left bundle-branch block	
174	Right ventricular MI	
N. Pacemaker		
180	Atrial-paced complex(es) or rhythm	
181	Ventricular-paced complex(es) or rhythm	
182	Ventricular pacing of non-right ventricular apical origin	
183	Atrial-sensed ventricular-paced complex(es) or rhythm	
184	AV dual-paced complex(es) or rhythm	
185	Failure to capture, atrial	
186	Failure to capture, ventricular	
187	Failure to inhibit, atrial	
188	Failure to inhibit, ventricular	
189	Failure to pace, atrial	
190	Failure to pace, ventricular	

 $\label{eq:AV indicates at rioventricular} \ \ \text{MI, myocardial infarction.}$

TABLE 2. Secondary Statements

TABLE El Cocondary Clatomonto	
Suggests	
200	Acute pericarditis
201	Acute pulmonary embolism
202	Brugada abnormality
203	Chronic pulmonary disease
204	CNS disease
205	Digitalis effect
206	Digitalis toxicity
207	Hypercalcemia
208	Hyperkalemia
209	Hypertrophic cardiomyopathy
210	Hypocalcemia
211	Hypokalemia or drug effect
212	Hypothermia
213	Ostium primum ASD
214	Pericardial effusion
215	Sinoatrial disorder
Consider	
220	Acute ischemia
221	AV nodal reentry
222	AV reentry
223	Genetic repolarization abnormality
224	High precordial lead placement
225	Hypothyroidism
226	Ischemia
227	Left ventricular aneurysm
228	Normal variant
229	Pulmonary disease
230	Dextrocardia
231	Dextroposition

 $\ensuremath{\mathsf{CNS}}$ indicates central nervous system; ASD, atrial septal defect; and AV, atrioventricular.

TABLE 3. Modifiers

General		Myocardial infarction, cont	'd
301	Borderline	332	Old
303	Increased	333	Of indeterminate age
304	Intermittent	334	Evolving
305	Marked	Arrhythmias and tachyarrh	ythmias
306	Moderate	340	Couplets
307	Multiple	341	In a bigeminal pattern
308	Occasional	342	In a trigeminal pattern
309	One	343	Monomorphic
310	Frequent	344	Multifocal
312	Possible	345	Unifocal
313	Postoperative	346	With a rapid ventricular response
314	Predominant	347	With a slow ventricular response
315	Probable	348	With capture beat(s)
316	Prominent	349	With aberrancy
317	(Specified) Lead(s)	350	Polymorphic
318	(Specified) Electrode(s)	Repolarization abnormalitie	9S
321	Nonspecific	360	≥0.1 mV
General: conjunctions		361	≥0.2 mV
302	Consider	362	Depression
310	Or	363	Elevation
320	And	364	Maximally toward lead
319	With	365	Maximally away from lead
322	Versus	366	Low amplitude
Myocardial infarction		367	Inversion
330	Acute	369	Postpacing (anamnestic)
331	Recent		

TABLE 4. Comparison Statements

Code	Statement	Criteria
400	No significant change	Intervals (PR, QRS, QTc) remain normal or within 10% of a previously abnormal value
		No new or deleted diagnoses with the exception of normal variant diagnoses
401	Significant change in rhythm	New or deleted rhythm diagnosis
		HR change $>$ 20 bpm and $<$ 50 or $>$ 100 bpm
		New or deleted pacemaker diagnosis
402	New or worsened ischemia or infarction	Added infarction, ST-ischemia, or T-wave-ischemia diagnosis, or worsened ST deviation or T-wave abnormality
403	New conduction abnormality	Added AV or IV conduction diagnosis
404	Significant repolarization change	New or deleted QT diagnosis
		New or deleted U-wave diagnosis
		New or deleted nonischemic ST or T-wave diagnosis
		Change in QTc >60 ms
405	Change in clinical status	New or deleted diagnosis from Axis and Voltage, Chamber Hypertrophy, or Enlargement primary statement categories or "Suggests" secondary statement category
406	Change in interpretation without significant change in waveform	Used when a primary or secondary statement is added or removed despite no real change in the tracing; ie, an interpretive disagreement exists between the readers of the first and second ECGs

TABLE 5. General Use Rules

- 1 Secondary statements must be accompanied by a primary statement
- 2 Modifiers must be accompanied by a primary statement
- 3 A primary statement may be accompanied by nothing, by ${\ge}1$ modifiers, by ${\ge}1$ secondary statements, or by both.
- 4 Each secondary statement can accompany only certain primary statements (see Table 6)
- 5 Each general modifier can accompany only certain primary statements (see Table 7)
- 6 Each specific modifier can accompany only primary statements within its category

TABLE 6. Secondary-Primary Statement Pairing Rules

	Trimary otatomont running nuico
Secondary Code	May Accompany These Primary Codes
200	145–147
201	21, 105, 109, 120, 131, 141, 145–147
202	105, 106, 145–146
203	109, 120, 125, 128, 131, 141, 143
204	147
205	145–147
206	145–147
207	149
208	147
209	142
210	148
211	147–148, 150
212	14, 154
213	82, 105–106, 121
214	124
215	42, 131, 145–147
220	145–147, 151
221	55, 56
222	55, 56
223	148, 149
224	128
225	22, 24–26, 37, 38
226	145–147
227	145–147
228	80, 105, 128, 155
229	109, 120, 122–123, 125, 128, 131, 141, 143
230	128, 131
231	128

TABLE 7. General Modifier-Primary Statement Pairing Rules*

General Modifier Code	May (May Not) Accompany These Primary Codes or May Be Between Codes in These Categories or Groups of Categories	May/ May Not	Location
301	1–20, 24–76, 81, 83–106, 108, 122–124	May not	b
302	1–3, 12–16, 80–82, 111–130, 145–152	May not	b, i
303	30, 31, 36, 37, 41, 60, 62, 63, 82, 107, 109, 110	May	a, b
304	21–26, 30–76, 80, 82–108, 124, 180–190	May	b
305	1–20, 27–76, 81, 85–106, 111, 122, 123, 148–150, 160–190	May not	b
306	1–20, 27–76, 81, 85–106, 111, 122, 123, 148–150, 160–190	May not	b
307	26, 30, 31, 36, 37, 41, 60–62, 185–190	May	b
308	26, 30, 31, 36, 37, 41, 60–62, 185–190	May	b
309	26, 30, 31, 36, 37, 41, 60–62, 185–190	May	b
310	C, D, E, F, G, N, H, I, J, K, L, M	May	i
312	1–3, 15, 80–82, 120–122, 128	May not	b
313	145–147	May	b
314	20-23, 33-35, 38-56, 63-76, 83-89, 180-184	May	b
315	1–3, 15, 80–82, 120–122, 128	May not	b
316	1–20, 27–76, 81, 85–106, 111, 122, 123, 148–150, 160–190	May not	b
317	C, D, E, F, G, N, H, I, J, K, L, M	May	i
318	C, D, E, F, G, N, H, I, J, K, L, M	May	i
319	C, D, E, F, G, N, 100, J, K, L, M	May	i
321	40, 55, 56, 145–147	May	b

b indicates before; a, after; and i, between.

TABLE 8. Convenience Statements*

Code	Statement
500	Nonspecific ST-T abnormality
501	ST elevation
502	ST depression
503	LVH with ST-T changes
	Others to be added

LVH indicates left ventricular hypertrophy.

^{*}Not inclusive.

^{*}This table will be developed independently by each ECG laboratory.